Defunct Company
Total Trials
12
As Lead Sponsor
11
As Collaborator
1
Total Enrollment
140
NCT03487263
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 1, 2017
Completion: Dec 30, 2018
NCT03875560
IC14 in Adult Patients With Dengue Fever
Phase: Phase 2
Start: May 31, 2019
Completion: Jun 30, 2020
NCT03017547
A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
Start: Jun 30, 2019
NCT03474263
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
Start: Sep 1, 2019
Completion: Jul 12, 2021
NCT04391309
COVID-19 and Anti-CD14 Treatment Trial
Role: Collaborator
Start: Apr 12, 2021
Completion: Feb 4, 2022
NCT03508453
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Start: Aug 15, 2021
Completion: Dec 15, 2023
NCT06275893
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy
Phase: Phase 1/2
Start: Mar 29, 2024
Completion: Dec 1, 2025
NCT06556810
IC14 for Treatment of Acute Decompensated Heart Failure
Start: Oct 17, 2024
Completion: Jan 31, 2026
NCT06678074
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Start: Feb 6, 2025
Completion: Sep 1, 2026
NCT06513949
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Start: Aug 15, 2025
Completion: Dec 31, 2027